Get the Stockscreener App
17.73
0.00%
0.00
After Hours:
17.50
-0.23
-1.30%
Zai Lab Limited Adr stock is traded at $17.73, with a volume of 354.98K.
It is up +0.00% in the last 24 hours and down -13.89% over the past month.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
See More
Previous Close:
$17.73
Open:
$17.87
24h Volume:
354.98K
Relative Volume:
0.42
Market Cap:
$1.99B
Revenue:
$454.68M
Net Income/Loss:
$-178.68M
P/E Ratio:
-10.94
EPS:
-1.6209
Net Cash Flow:
$-135.66M
1W Performance:
+6.49%
1M Performance:
-13.89%
6M Performance:
+4.29%
1Y Performance:
-56.36%
1-Day Range:
$17.62
$17.96
1-Week Range:
$16.76
$18.06
52-Week Range:
$15.96
$41.20
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Name
Zai Lab Limited Adr
Sector
Industry
Phone
862161632588
Address
899 HALEI ROAD, SHANGHAI
Compare ZLAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
17.73 | 1.99B | 454.68M | -178.68M | -135.66M | -1.6209 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Resumed | Jefferies | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-14-23 | Initiated | Morgan Stanley | Overweight |
| Aug-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-22 | Initiated | Macquarie | Outperform |
| Oct-12-21 | Initiated | Bernstein | Mkt Perform |
| Apr-28-20 | Initiated | Goldman | Buy |
| Apr-15-20 | Initiated | Guggenheim | Buy |
| Jul-12-19 | Initiated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
| Jan-29-19 | Initiated | Credit Suisse | Outperform |
| Nov-21-18 | Initiated | Jefferies | Buy |
| Jun-21-18 | Resumed | Leerink Partners | Outperform |
| Feb-14-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Initiated | JP Morgan | Neutral |
| Oct-16-17 | Initiated | Leerink Partners | Outperform |
View All
Zai Lab Limited Adr Stock (ZLAB) Latest News
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas - Business Wire
Number of shareholders of Zai Lab Ltd. Sponsored ADR – SWB:1ZL - TradingView
TCG Crossover funds, Chen Yu hold 5.3% of ZLAB (ADS positions) - Stock Titan
China’s TIVDAK Approval in Advanced Cervical Cancer Could Be A Game Changer For Zai Lab (ZLAB) - Sahm
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer - BioSpace
Trial's China arm: TIVDAK cuts death risk 45% vs chemo in cervical cancer - Stock Titan
(tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer - Business Wire
Equity grants for Zai Lab (ZLAB) operating partner Wang Yizhe - Stock Titan
Zai Lab (ZLAB) Operating Partner Wang Yizhe listed as insider on Form 3 - Stock Titan
Zai Lab Ltd (ADR) stock (CA98959U1084): Oncology pipeline and US listing in focus - AD HOC NEWS
UnitedHealth, Regeneron Pharmaceuticals and other big stocks moving lower in Monday's pre-market session - MSN
Zai Lab (NASDAQ: ZLAB) CEO gifts 107,700 ADS to adult son’s trusts - Stock Titan
Zai Lab Announces Changes to Senior Leadership Team - Business Wire
Zai Lab Ltd stock (US98887Q1040): analyst downgrade adds pressure after biotech news flow - AD HOC NEWS
Zai Lab Ltd stock (KYG9887Y1016): recent earnings and oncology pipeline in focus - AD HOC NEWS
Zai Lab (NASDAQ: ZLAB) president and COO departs; CEO assumes duties - Stock Titan
Zai Lab (ZLAB) CEO sells 100,000 ADS in Rule 10b5-1 trades - Stock Titan
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
CICC Cuts ZAI LAB (09688.HK) TP to HKD20.2; 1Q Results In Line - AASTOCKS.com
Ying Du files Form 144 to sell ADS blocks (ZLAB) - Stock Titan
Zai Lab (ZLAB) CLO sells 3,517 ADS under Rule 10b5-1 plan - Stock Titan
Zai Lab (ZLAB) CEO exercises 100K options and sells 100K ADSs under plan - Stock Titan
ZLAB (NASDAQ: ZLAB) insider files multiple ADS sale notices totaling repeated 50,000‑share lines - Stock Titan
BOCI Downgrades ZAI LAB (09688.HK) to Hold, Halves TP to HKD17 - AASTOCKS.com
Ying Du sells multiple American Depositary Shares (ZLAB) across March–May 2026 - Stock Titan
KE Holdings Inc American Depositary Shares (each representing three Class A (NY: BEKE - FinancialContent
ZLAB (NASDAQ) insider reports ADS sales totaling multiple tranches in March–April 2026 - Stock Titan
50,000 ADS sale notice for ZLAB (NASDAQ: ZLAB) on 05/13/2026 - Stock Titan
M Stanley Cuts ZAI LAB (09688.HK) TP to HKD19, Reflecting Post-1Q Results Forecast Revisions - AASTOCKS.com
Zai Lab Limited (NASDAQ:ZLAB) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) - ChartMill
Zai Lab Q1 Earnings Call Highlights - Yahoo Finance
ZAI LAB (09688.HK) 1Q Net Loss Widens to USD51.02 million - AASTOCKS.com
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Zai Lab (NASDAQ: ZLAB) Q1 revenue dips 6% as ZEJULA weakens - Stock Titan
Zai Lab (NASDAQ: ZLAB) Q1 2026 revenue slips as R&D and ADC pipeline advance - Stock Titan
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates - ChartMill
Which Is a Better Investment, AnaptysBio, Inc. or Zai Lab Limited Stock? - AAII.com
Zai Lab (ZLAB) Expected to Announce Earnings on Thursday - MarketBeat
Zai Lab (NASDAQ: ZLAB, HKEX: 9688) details 2026 AGM votes on board, pay, 10% mandates - Stock Titan
BofAS Raises Zai Lab (09688.HK) TP to HKD18.6, Rating Neutral - AASTOCKS.com
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Zai Lab Showcases 54% Brain Metastases Response for ZL-1310 ADC in SCLC at AACR Investor Call - Yahoo Finance
Assessing Zai Lab (NasdaqGM:ZLAB) Valuation After Recent Share Price Momentum Shift - Sahm
Zai Lab (NASDAQ:ZLAB) Trading Down 5.2%Here's What Happened - MarketBeat
How many employees work at Zai Lab? - Revelio Labs
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026 - BioSpace
Zai Lab Ltd (ADR) stock (CA98959U1084): Why Google Discover changes matter more now - AD HOC NEWS
Zai Lab Ltd stock (US98887Q1040): Is its China oncology focus strong enough to unlock new upside? - AD HOC NEWS
Zai Lab and Amgen Launch Clinical Trial for Lung Cancer Therapy - HarianBasis.co
Zai Lab (ZLAB), Amgen (AMGN) Partner to Evaluate Combination Lung Cancer Therapy - Yahoo Finance
Zai Lab Limited Adr Stock (ZLAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zai Lab Limited Adr Stock (ZLAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Du Ying | Chairperson & CEO |
May 15 '26 |
Option Exercise |
1.74 |
50,000 |
87,000 |
1,172,626 |
| Du Ying | Chairperson & CEO |
May 18 '26 |
Option Exercise |
1.74 |
50,000 |
87,000 |
1,172,626 |
| Du Ying | Chairperson & CEO |
May 15 '26 |
Sale |
20.74 |
50,000 |
1,037,110 |
1,122,626 |
| Du Ying | Chairperson & CEO |
May 18 '26 |
Sale |
19.00 |
50,000 |
949,765 |
1,122,626 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):